BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) ...
CAMBRIDGE, Mass. & SINGAPORE--(BUSINESS WIRE)--Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung ...
Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...
The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback